Year All2024202320222021202020192018201720162015 Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer July 20, 2018 Poseida Therapeutics Appoints John P. Schmid to Board of Directors July 19, 2018 Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA April 26, 2018 Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma April 17, 2018 Poseida Raises $30.5 Million in Series B Financing April 3, 2018 Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018 March 26, 2018 Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer February 28, 2018 Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies February 14, 2018 Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations February 5, 2018 Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma December 18, 2017
Poseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer July 20, 2018
Poseida Therapeutics Presents Clinical Manufacturing Method for Durable, Persistent CAR-T Stem Cell Memory Therapies at World Orphan Drug Congress USA April 26, 2018
Poseida Announces Initial Phase 1 Data for P-BCMA-101 CAR-T Stem Cell Memory Product in Patients with Relapsed/Refractory Multiple Myeloma April 17, 2018
Poseida to Present P-BCMA-101 Phase 1 Data at the American Association for Cancer Research (AACR) Annual Meeting 2018 March 26, 2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer February 28, 2018
Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies February 14, 2018
Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations February 5, 2018
Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma December 18, 2017